This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Gilead Sciences, Inc., Nurix Therapeutics, Inc.. Active years: 2024.
Company Filing History:
1 out of 946 
1 out of 22 Years Active: 2024
Title: Ryan Pemberton: Innovator in Therapeutic Compounds
Introduction
Ryan Pemberton is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of therapeutic compounds, particularly through his innovative patent work. His expertise lies in developing compounds that target specific pathways in disease modulation.
Latest Patents
Ryan holds a patent titled "Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof." This patent presents bifunctional compounds that act as HPK1 degraders via the ubiquitin proteasome pathway. The method outlined in his patent offers potential treatments for diseases modulated by HPK1.
Career Highlights
Throughout his career, Ryan has worked with prominent companies in the biotechnology sector. He has been associated with Gilead Sciences, Inc. and Nurix Therapeutics, Inc., where he has contributed to advancing therapeutic innovations. His work has been instrumental in developing new approaches to treating complex diseases.
Collaborations
Ryan has collaborated with esteemed colleagues in his field, including Frederick Cohen and Mark Edward Zak. These partnerships have fostered a collaborative environment that enhances the development of innovative therapeutic solutions.
Conclusion
Ryan Pemberton is a distinguished inventor whose work in therapeutic compounds has the potential to impact the treatment of various diseases. His innovative approach and collaborations with leading companies and professionals highlight his commitment to advancing medical science.